Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Cell Immunotherapy + Chemotherapy in Advanced Gastric Cancer
NCT02862561Phase 2Unknown
- Sponsor
- Shanghai International Medical Center
- Start
- Aug 2016
- Primary completion
- Mar 2018
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of precision cells in gastric cancer (GC) (2 arms), sponsored by Shanghai International Medical Center. Primary endpoints: Overall Survival at 2 years and Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
precision cells
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02862561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02862561.